UNSPSC 51372806: Nefopam hydrochloride

This classification denotes a benzodiazepine with the molecular formula C17H19NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 685J48E13W, chemically known as 3,4,5,6-tetrahydro-5-methyl-1-phenyl-1h-2,5-benzoxazocine hydrochloride but more generally known as nefopam hydrochloride, which bears US NIH Compound Identifier 31872. European Medicines Agency schedules Nefopam hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03400MIG.

Most nations, for tariff and trade purposes, schedule nefopam hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, NEFOPAM HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Nefopam hydrochloride bears US NLM identifiers UMLS ID C0015820 and NCI Concept Code C83995. SMILES: CN1CCOC(C2CCCCC2C1)C3CCCCC3.CL.

UNSPSC 51372806 Nefopam hydrochloride is a Commodity code that nominally identifies a specific pharmaceutical substance, but recent state and local solicitations tagged under it show minimal alignment with nefopam procurement itself. Instead, the code appears in opportunities focused on broader pharmaceutical and drug-intervention products — naloxone, generic multi-source pharmaceuticals, and over-the-counter products — that state and local health and social-services agencies are actively purchasing. The work involves establishing supply contracts for pharmaceutical products distributed through existing wholesaler networks or direct delivery to county health facilities, with vendors required to meet federal drug-manufacturing standards (cGMP, DSCSA compliance), maintain insurance coverage, and in some cases accept administrative fees or performance penalty structures.

Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (MMCAP, administered by Minnesota Department of Administration and involving multiple states including Oregon). Activity spans Florida, Texas, and the upper Midwest. Representative recent opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries (response deadline July 26, 2023); Texas HHS Commission's RFI on direct-to-manufacturer prescription programs (response deadline April 3, 2026); and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products through authorized wholesalers with proposals due March 26, 2026. The MMCAP procurement is the most mature and broadly scoped, requiring vendors to provide comprehensive NDC pricing, maintain relationships with at least two of three authorized wholesalers, and accept a 3 percent administrative fee on all purchases with performance penalties ranging from $200 to $1,500 per violation.